Tyrosine kinase
Top View
- Novel Roles of Erbb3 Receptor Tyrosine Kinase in Vesicular Trafficking
- Small Molecule Tyrosine Kinase Inhibitors of Erbb2/HER2/Neu in the Treatment of Aggressive Breast Cancer
- Receptor Tyrosine Kinase Signalling As a Target for Cancer Intervention Strategies
- Harnessing the Power of Eph/Ephrin Biosemiotics for Theranostic Applications
- Trastuzumab Is Not a Tyrosine Kinase Inhibitor Nishant Mohan and Wen Jin Wu
- Pdgfrβ Kinase Assay by Jolanta Vidugiriene, Ph.D., Hicham Zegzouti, Ph.D., and Said A
- THE ROLE of the Ret PROTO-ONCOGENE in HUMAN DISEASE
- C-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences
- Clinical Use of Tyrosine Kinase Inhibitors: Therapy for Chronic Myelogenous Leukemia and Other Cancers
- A Tyrosine Kinase-Activating Variant Asn666ser in PDGFRB Causes a Progeria-Like Condition in the Severe End of Penttinen Syndrome
- Mechanisms of Receptor Tyrosine Kinase Activation in Cancer Zhenfang Du1 and Christine M
- Exploiting Insights on the RET Receptor for Personalized Cancer Medicine
- Structure and Regulation of Kit Protein-Tyrosine Kinase—The Stem Cell Factor Receptor Q
- De-Repression of Pdgfrb Transcription Promotes Acquired
- TNF Down-Regulation of Receptor Tyrosine Kinase
- Novel Therapeutic Inhibitors of the C-Met Signaling Pathway in Cancer Joseph Paul Eder,1George F
- Oncogenic Mutation in the Kit Receptor Tyrosine Kinase Alters Substrate
- Erbb3/HER3 Intracellular Domain Is Competent to Bind ATP and Catalyze Autophosphorylation